Genetic mouse models of Parkinsonism: Strengths and limitations

被引：117

作者：

Fleming S.M. ^{[1
]}

Fernagut P.-O. ^{[1
]}

Chesselet M.-F. ^{[1
,2
]}

机构：

[1] Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles

[2] Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095-1769

来源：

NeuroRX | 2005年 / 2卷 / 3期

关键词：

DJ-1; Mice; Nurr1; Parkin; Pitx3; α-Synuclein;

D O I：

10.1602/neurorx.2.3.495

中图分类号：

学科分类号：

摘要：

Parkinson's disease (PD) is a progressive neurodegenerative disorder. Patients with PD display a combination of motor symptoms including resting tremor, rigidity, bradykinesia, and postural instability that worsen over time. These motor symptoms are related to the progressive loss of dopamine neurons in the substantia nigra pars compacta. PD patients also suffer from nonmotor symptoms that may precede the cardinal motor symptoms and that are likely related to pathology in other brain regions. Traditional toxin models of PD have focused on the nigrostriatal pathway and the loss of dopamine neurons in this region, and these models have been important in our understanding of PD and in the development of symptomatic treatments for the disease. However, they are limited in that they do not reproduce the full pathology and progression seen in PD, thus creating a need for better models. The recent discovery of specific genes causing familial forms of PD has contributed to the development of novel genetic mouse models of PD. This review discusses the validity, benefits, and limitations of these new models. © The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：495 / 503

页数：8

共 85 条

[31] Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M., Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein, Neuron, 34, pp. 521-533, (2002)
[32] Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., Sondel J., Kotilinek L., Day J., Schwarzschild M.A., Cha J.H., Newell K., Miller D.W., Ueda K., Young A.B., Hyman B.T., Ashe K.H., Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice, Neurobiol Aging, 24, pp. 245-258, (2003)
[33] Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J., Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice, Exp Neurol, 175, pp. 35-48, (2002)
[34] Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C.W., Lang I., Masliah E., Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters, J Neurosci Res, 68, pp. 568-578, (2002)
[35] Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L., Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders, Science, 287, pp. 1265-1269, (2000)
[36] Gispert S., Del Turco D., Garrett L., Chen A., Bernard D.J., Hamm-Clement J., Korf H.W., Deller T., Braak H., Auburger G., Nussbaum R.L., Transgenic mice expressing mutant A53T human α-synuclein show neuronal dysfunction in the absence of aggregate formation, Mol Cell Neurosci, 24, pp. 419-429, (2003)
[37] Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A., Richfield E.K., Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice, Eur J Neurosci, 19, pp. 845-854, (2004)
[38] Song D.D., Shults C.W., Sisk A., Rockenstein E., Masliah E., Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP, Exp Neurol, 186, pp. 158-172, (2004)
[39] Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F., Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein, J Neurosci, 24, pp. 9434-9440, (2004)
[40] Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., Kuhl D.E., Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging, Ann Neurol, 40, pp. 873-884, (1996)

← 1 2 3 4 5 6 7 8 9 →